Literature DB >> 23318536

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation.

A Garfall, H T Kim, L Sun, V T Ho, P Armand, J Koreth, E P Alyea, R J Soiffer, J H Antin, J Ritz, C Cutler.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23318536     DOI： 10.1038/bmt.2012.272

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

Review 1.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Authors:  P Rettman; F Malard; N Legrand; O Avinens; J-F Eliaou; C Picard; A Dormoy; X Lafarge; M de Matteis; A Kennel; P Loiseau; A Devys; A Boudifa; L Absi; M Fort; D Masson; F Quainon; I Theodorou; A Batho; A Parissiadis; F Delbos; M Drouet; D Senitzer; E Marry; N Raus; I Yakoub-Agha; A Cesbron; C Retière; K Gagne
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

Review 3.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

4.  Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.

Authors:  Vanderson Rocha; Annalisa Ruggeri; Stephen Spellman; Tao Wang; Ronald Sobecks; Franco Locatelli; Medhat Askar; Gerard Michel; William Arcese; Anna Paola Iori; Duncan Purtill; Robert Danby; Guillermo F Sanz; Eliane Gluckman; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-16       Impact factor: 5.742

Review 5.  NK cell therapy for hematologic malignancies.

Authors:  Rohtesh S Mehta; Brion Randolph; May Daher; Katayoun Rezvani
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

6.  Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.

Authors:  Carmen Martínez-Losada; Carmen Martín; Rafael Gonzalez; Bárbara Manzanares; Estefania García-Torres; Concha Herrera
Journal:  Front Immunol       Date:  2017-07-13       Impact factor: 7.561

Review 7.  Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications.

Authors:  Anushruti Sarvaria; Dunia Jawdat; J Alejandro Madrigal; Aurore Saudemont
Journal:  Front Immunol       Date:  2017-03-23       Impact factor: 7.561

8.  Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission.

Authors:  J Tanaka; Y Morishima; Y Takahashi; T Yabe; K Oba; S Takahashi; S Taniguchi; H Ogawa; Y Onishi; K Miyamura; H Kanamori; N Aotsuka; K Kato; S Kato; Y Atsuta; Y Kanda
Journal:  Blood Cancer J       Date:  2013-11-29       Impact factor: 11.037

Review 9.  Cord Blood as a Source of Natural Killer Cells.

Authors:  Rohtesh S Mehta; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Front Med (Lausanne)       Date:  2016-01-05

10.  Use of the HLA-B leader to optimize cord blood transplantation

Authors:  Effie W Petersdorf; Ted Gooley; Fernanda Volt; Chantal Kenzey; Alejandro Madrigal; Caroline McKallor; Sergio Querol; Hanadi Rafii; Vanderson Rocha; Ryad Tamouza; Christian Chabannon; Annalisa Ruggeri; Eliane Gluckman
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.